Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis

Abstract

Objective: To review the efficacy, safety, and place in therapy of ixekizumab for the treatment of moderate to severe plaque psoriasis. Data Sources: PubMed (1966 to July 2018) and clinicaltrials.gov were searched using the terms ixekizumab, LY2439821, interleukin-17, and psoriasis. Study Selection and Data Extraction: Human studies published in peer-reviewed medical journals in English were used. Data Synthesis: The efficacy and safety of ixekizumab has been primarily reported by 4 phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, and UNCOVER-J) and multiple post hoc analyses. The average proportions of patients achieving a 75%, 90%, and 100% reduction in their Psoriasis Area and Severity Index (PASI) were 89%, 70%, and 38%, respectively, after 12 weeks of therapy. PASI75 was maintained for up to 3 years in 80.5% of participants. Ixekizumab was statistically significantly more effective than ustekinumab, with 76.5%, compared with 59%, of patients achieving PASI90 in 52 weeks. The most common adverse events include nasopharyngitis (14.1%), upper respiratory tract infections (7.9%), and injection-site reactions (6.8%), which are similar to that for other biological agents. The risk of inflammatory bowel disease may be increased with ixekizumab. Relevance to Patient Care and Clinical Practice: This review summarizes and evaluates clinical data regarding the efficacy and safety of ixekizumab and discusses relevant differences compared with other biological agents used for the management of chronic plaque psoriasis. Conclusions: Ixekizumab is a highly efficacious and well-tolerated treatment option for patients with moderate to severe plaque psoriasis.

Keywords

psoriasis interleukins formulary cost-effectiveness dermatology

Get full access to this article

View all access options for this article.

References

Menter

Gottlieb

Feldman

et al . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.

Centers for Disease Control and Prevention. Psoriasis. https://www.cdc.gov/psoriasis/. Accessed June 30, 2018.

Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2010: Results by Cause 1990-2010. Seattle, WA: Institute of Health Metrics and Evaluation; 2012.

Boehncke

Schon

MP.

Psoriasis. Lancet. 2015;386:983-994.

World Health Organization. Global report on psoriasis. http://apps.who.int/iris/handle/10665/204417. Accessed June 30, 2018.

Sampogna

Tabolli

Abeni

; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92:299-303.

American Academy of Dermatology and AAD Association. Position statement on treatment of psoriatic patients. https://www.aad.org/Forms/Policies/Uploads/PS/PS%20on%20Treatment%20of%20Psoriatic%20Patients.pdf. Published April 27, 2013. Accessed August 14, 2018.

Menter

Korman

Elmets

et al . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-485.

Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.

10.

Humira [package insert]. North Chicago, IL: AbbVie Inc; 2018.

11.

Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2018.

12.

Remicade [package insert]. Horsham, PA: Janssen Biotech Inc; 2018.

13.

Siliq [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals; 2017.

14.

Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

15.

Stelara [package insert]. Horsham, PA: Janssen Biotech Inc; 2018.

16.

Tremfya [package insert. Horsham, PA: Janssen Biotech Inc; 2018.

17.

Ilumya [package insert]. Whitehouse Station, NJ: Merck and Co Inc; 2018.

18.

Chandrakumar

Yeung

Interleukin-17 antagonists in the treatment of psoriasis. J Cutan Med Surg. 2015;19:109-114.

19.

Tham

Tang

Choi

Satterwhite

Cameron

Banerjee

Population exposure-response model to support dosing evaluating of ixekizumab in patients with chronic plaque psoriasis. J Clin Pharmacol. 2014;54:1117-1124. doi:10.1002/jcph.312

20.

Duffin

Bagel

Bukhalo

et al . Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31:107-113. doi:10.1111/jdv.13768

21.

Wang

Balthasar

JP.

Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548-558. doi:10.1038/clpt.2008.170

22.

Genovese

Van den Bosch

Roberson

et al . LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62:929-939. doi:10.1002/art.27334

23.

Leonardi

Matheson

Zachariae

et al . Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-1199.

24.

Gordon

Leonardi

Lebwohl

et al . A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176-1182.

25.

Zachariae

Gordon, Kimball

et al . Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018;79:294-301.e6. doi:10.1016/j.jaad.2018.03.047

26.

Griffiths

Reich

Lebwohl

et al ; UNCOVER-2 and UNCOVER-3 Investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet. 2015;386:541-551. doi:10.1016/S0140-6736(15)60125-8

27.

Gordon

Blauvelt

Papp

et al ; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-sever plaque psoriasis. N Engl J Med. 2016;375:345-356.

28.

Saeki

Nakagawa

Nakajo

et al ; Japanese Ixekizumab Study Group. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355-362.

29.

Blauvelt

Gooderham

Iversen

et al . Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77:855-862.

30.

Leonardi

Maari

Phillipp

et al . Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79:824-830.

31.

Gottlieb

Lacour

Korman

et al . Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31:679-685.

32.

Blauvelt

Papp

Griffiths

CEM

. Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. 2017;18:273-280.

33.

Reich

Puig

Mallbris

Zhang

Osuntokun

Leonardi

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomized, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1196-1207.

34.

Blauvelt

Papp KA

Sofen

et al . Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1004-1013.

35.

van de Kerkhof

Guenther

Gottlieb

et al . Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:477-482.

36.

Reich

Leonardi

Lebwohl

et al . Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28:282-287.

37.

Kimball

Luger

Gottlieb

et al . Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75:1156-1161.

38.

Leonardi

Blauvelt

Sofen

et al . Rapid improvement in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:1483-1490.

39.

Kimball

Luger

Gottlieb

et al . Long-term impact of ixekizumab on psoriasis itch severity: results from a phase III clinical trial and long-term extension. Acta Derm Venereol. 2018;98:98-102.

40.

Guenther

Warren

Cather

et al . Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two phase 3 trials. J Eur Acad Dermatol Venereol. 2017;31:1867-1875.

41.

Paul

Guenther

Torii

et al . Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-sever psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2018;32:68-72.

42.

Georgakopoulos

Phung

Ighani

Yeung

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of the interleukin (IL)-17A antagonist therapies. J Am Acad Dermatol. 2018;79:155-157. doi:10.1016/j.jaad.2018.01.003

43.

Reich

Pinter

Lacour

et al ; IXORA-S investigators. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014-1023.

44.

Paul

Griffiths

CEM

van de Kerkhof

PCM

et al . Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80:70-79.

45.

Zhu

Edon-Heredeia

Cameron

et al . Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169:1337-1341.

46.

Langley

Rich

Menter

et al . Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1763-1770.

47.

Strober

Leonardi

Papp

et al . Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432-440.

48.

Reich

Leonardi

Langley

et al . Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76:441-448.e2.

49.

Orrell

Murphrey

Kelm

et al . Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: a post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program. J Am Acad Dermatol. 2018;79:777-778.

50.

Papp

Bachelez

Blauvelt

et al . Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017;177:1537-1551.

51.

American Academy of Dermatology Work Group; Menter

Korman

et al . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-174.

52.

Hsu

Papp

Lebwohl

et al ; National Psoriasis Foundation Medical Board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95-102.

53.

de Carvalho

Duquia

Horta

Bonamigo

RR.

Efficacy of immunobiologic and small molecule inhibitors drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2017;17:29-51. doi:10.1007/s40268-016-0152

54.

Loos

Liu

Segel

Ollendorf

Pearson

Linder

JA.

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2018;79:135-144.e7.

55.

Bilal

Berlinberg

Bhattacharjee

Trost

Riaz

Kurtzman

DJB

. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29:569-578.

56.

Armstrong

Betts

Signorovitch

et al . Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34:1325-1333. doi:10.1080/03007995.2018.1457516

57.

Warren

Brnabic

Saure

et al . Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs secukinumab. Br J Dermatol. 2018;178:1064-1071.

58.

Feldman

Rastogi

Menges

Lingohr-Smith

Lin

. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29:769-774.